Supplier log in
RFP - Supply of Permanent Coronary Drug-Eluting Stents
Details
|
Tender Closed
|
|
| RFx ID : | 25604367 |
| Tender Name : | RFP - Supply of Permanent Coronary Drug-Eluting Stents |
| Reference # : | A1539175 |
| Open Date : | Tuesday, 29 March 2022 9:00 AM (Pacific/Auckland UTC+13:00) |
| Close Date : | Tuesday, 26 April 2022 5:00 PM (Pacific/Auckland UTC+12:00) |
| Tender Type : | Request for Proposals (RFP) |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Exemption Reason : | None |
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@pharmac.govt.nz . |
| Alternate Physical Delivery Address : | |
| Alternate Physical Fax Number : | |
| Agency Address : | |
Pharmac invites proposals for the supply of Permanent Coronary Drug-Eluting Stents in New Zealand.
The request for proposals (RFP) letter attached to this listing incorporates the following schedules:
· Schedule 1 sets out the background to the RFP and the range of devices included and types of proposals sought;
· Schedule 2 describes the process that Pharmac expects to follow in relation to the RFP;
· Schedule 3 sets out information about the estimated size of the current market for the devices;
· Schedule 4 specifies the information and evidence you need to include in your proposal;
· Schedule 5 and Attachments 1, 2, 4 and 5 contain the forms in which you are to provide the details of your proposal; and
· Attachment 3 contains the Pharmac terms and conditions to list medical devices on the Pharmaceutical Schedule.
All proposals must be submitted to Pharmac via the Government Electronic Tenders Service (GETS) no later than 5.00pm Tuesday 26 April 2022.
The Permanent Coronary Drug-Eluting Stents which are in scope and out of scope of this RFP are outlined further in Schedule 1, clause 5.
As the market share procurement model for medical devices may be new for some suppliers, we will provide an opportunity for Pharmac staff to answer any questions you might have regarding this RFP process. We expect to hold one supplier briefing meeting via Zoom at 3.00pm on Tuesday 5 April 2022. Please refer to page 6 of the RFP letter for more information.
We look forward to receiving your proposal.
This tender has been awarded.
- Boston Scientific New Zealand Limited - 3 Diamond Street, Eden Terrace, Auckland, 1021, NEW ZEALAND
Further Award Information:
Pharmac is pleased to announce the approval of a market share agreement progressed through an open RFP for supply of permanent coronary drug-eluting stents (“DES”).
Pharmac has decided to award Principal Supply Status (“PSS”) to Boston Scientific New Zealand Limited (“Boston”) for the supply of DES to Te Whatu Ora hospitals, with a 35% Alternative Brand Allowance (“ABA”).
In summary this will result in:
• Boston’s brands of DES, Promus Elite, Synergy XD and Synergy Megatron, being listed in Part III of Section H of the Pharmaceutical Schedule and available for Te Whatu Ora hospitals at reduced prices from 1 November 2022;
• a transition period from 1 November 2022 until 28 February 2023 will apply;
• Promus Elite, Synergy XD and Synergy Megatron having PSS from 1 March 2023 until 28 February 2026. During this period 65% of all DES purchases by Te Whatu Ora hospitals must be one of Boston’s brands.
• estimated annual savings of over $735,000 across all Te Whatu Ora hospitals.
Please note:
• This agreement was provisional on consultation and final approval from the Pharmac Board or its delegate. The notification date is the ‘approval’ or award date.
• The 5 October 2022 award notification is available on the Pharmac website here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-10-05-des-boston/.
• The terms of the agreement are based on Pharmac’s standard terms and conditions to list medical devices on the Pharmaceutical Schedule, which are available as a download on the RFP page which can be accessed here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/rfp-2022-03-29-devices-des/?type=RFP&page=1.
• The approximate gross annual Te Whatu Ora hospitals expenditure for DES is $6.5 million.
• Pharmac is committed to sustainable and inclusive procurement that delivers for New Zealand and New Zealanders. Broader outcomes were considered in this process.
Award Date: Wednesday, 5 October 2022 (Pacific/Auckland UTC+13:00)
Date RFx was completed/updated: Monday, 17 October 2022 6:15 PM (Pacific/Auckland UTC+13:00)
